NSD2 and its H3K36 methyltransferase activity recruit AR to tumor-specific enhancers, where it cooperates with pioneer factors such as FOXA1, HOXB13, and ETS, redistributing AR binding and amplifying oncogenic signaling (24). Here, FOXA1 is linked to neoplasm.